Myelofibrosis with a novel translocation, t(1;3)(q31;q23), and response to imatinib mesylate.
Yalamanchili
K
K
Liu
D
D
Seiter
K
K
D015703:Antigens, CD / Q000032:analysis; D001549:Benzamides; D001854:Bone Marrow Cells / Q000737:chemistry / Q000473:pathology; D002878:Chromosomes, Human, Pair 1 / Q000235:genetics* / Q000648:ultrastructure; D002893:Chromosomes, Human, Pair 3 / Q000235:genetics* / Q000648:ultrastructure; D006801:Humans; D000068877:Imatinib Mesylate; D008297:Male; D008875:Middle Aged; D010879:Piperazines / Q000627:therapeutic use*; D055728:Primary Myelofibrosis / Q000188:drug therapy / Q000235:genetics* / Q000473:pathology; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D011743:Pyrimidines / Q000627:therapeutic use*; D011799:Quinazolines / Q000009:adverse effects / Q000627:therapeutic use; D012074:Remission Induction; D013163:Splenomegaly / Q000188:drug therapy / Q000209:etiology; D014178:Translocation, Genetic
D015703:Antigens, CD; D001549:Benzamides; D010879:Piperazines; D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D011799:Quinazolines; D000068877:Imatinib Mesylate; C021139:anagrelide